An overview of FDA-approved biologics medicines. Issue 4 (April 2015)

• Record Type: Journal Article
• Authors: Kinch, Michael S.
• Is Part Of: Drug discovery today. Volume 20:Issue 4(2015)
• Page Start: 393
• Page End: 398
• Publication Date: 2015-04
• Subjects: Drugs -- Design -- Periodicals; Drugs -- Research -- Periodicals; 615.1
• DOI: 10.1016/j.drudis.2014.09.003
• Languages: English
• ISSNs: 1359-6446

Abstract

<abstract abstract-type="author-highlights" id="abs0005"> <title id="sect0005">Highlights</title> <sec> <p id="spar0005"> <list id="lis0005"> <list-item id="lsti0005"> <label></label> <p id="par0005">Biologics approvals grew from the early 1980s through 2010, stabilizing thereafter.</p> </list-item> <list-item id="lsti0010"> <label></label> <p id="par0010">Three different disease categories capture more than 70% of initial antibody approvals.</p> </list-item> <list-item id="lsti0015"> <label></label> <p id="par0015">The relative number of biologics (to small molecules) might be declining.</p> </list-item> </list> </p> </sec> </abstract>